Zimmer Biomet Holdings, Inc. $ZBH Holdings Lifted by State Street Corp

Key Points

• Institutional ownership increased: State Street raised its Zimmer Biomet stake by 0.6% to 8.88 million shares, while institutional investors and hedge funds collectively own 88.89% of the company.
• Quarterly results exceeded expectations: Zimmer Biomet reported $2.07 in adjusted EPS and $2.18 billion in revenue, beating estimates and marking 4.8% year-over-year revenue growth. The company projects fiscal 2026 EPS of $8.47–$8.59.
• Analysts remain cautious: The stock has a consensus “Hold” rating with an average price target of $103, compared with a recent share price of $91.05. Zimmer Biomet also declared a quarterly dividend of $0.24 per share, yielding approximately 1.1% annually.

State Street Corp boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 0.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,877,171 shares of the medical equipment provider's stock after acquiring an additional 52,044 shares during the quarter. State Street Corp owned about 4.65% of Zimmer Biomet worth $766,343,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZBH. BlackRock Inc. bought a new stake in shares of Zimmer Biomet in the 2nd quarter worth approximately $1,344,282,000. Franklin Resources Inc. grew its position in Zimmer Biomet by 43.2% in the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider's stock worth $601,204,000 after buying an additional 2,017,857 shares during the last quarter. Geode Capital Management LLC grew its position in Zimmer Biomet by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 5,233,834 shares of the medical equipment provider's stock worth $468,821,000 after buying an additional 36,611 shares during the last quarter. Primecap Management Co. CA bought a new position in shares of Zimmer Biomet in the second quarter valued at $328,578,000. Finally, Van ECK Associates Corp lifted its position in shares of Zimmer Biomet by 3.9% during the 4th quarter. Van ECK Associates Corp now owns 3,613,425 shares of the medical equipment provider's stock valued at $324,920,000 after acquiring an additional 136,519 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $91.05 on Thursday. The company's fifty day moving average is $96.31 and its two-hundred day moving average is $91.30. The company has a market cap of $17.37 billion, a P/E ratio of 22.15, a price-to-earnings-growth ratio of 1.77 and a beta of 0.47. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $106.88. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts' expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.Zimmer Biomet's revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet's dividend payout ratio (DPR) is presently 23.36%.

Insider Activity

In other news, insider Chad Phipps sold 3,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares of the company's stock, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. Insiders own 1.28% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Canaccord Genuity Group lifted their target price on Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a report on Monday, August 10th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a report on Thursday, August 6th. Stifel Nicolaus increased their price target on Zimmer Biomet from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Sanford C. Bernstein lifted their price target on Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a research note on Thursday, August 6th. Finally, Citigroup cut their price objective on Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating on the stock in a report on Thursday, May 28th. Six research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $103.00.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc NYSE: ZBH is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.